Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled Phase 3 study of RO7239361 in ambulatory boys with Duchenne muscular dystrophy
2016-001654-18Phase 3Terminated
- Sponsor
- Roche
- Start
- Jun 2017
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing RO7239361 with Placebo (2 arms). Started Jun 2017; status: terminated.
02
Drugs
taldefgrobep alfa
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2016-001654-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001654-18.